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Summary 
By using a systems based approach, mathematical and computational techniques can be used 
to develop models that describe the important mechanisms involved in infectious diseases. An 
iterative approach to model development allows new discoveries to continually improve the 
model, and ultimately increase the accuracy of predictions. 
 
SIR models are used to describe epidemics, predicting the extent and spread of disease. 
Genome-wide genotyping and sequencing technologies can be used to identify the biological 
mechanisms behind diseases. These tools help to build strategies for disease prevention and 
treatment, an example being the recent outbreak of Ebola in West Africa where these 
techniques were deployed. 
 
HIV is a complex disease where much is still to be learnt about the virus and the best 
effective treatment. With basic mathematical modelling techniques, significant discoveries 
have been made over the last 20 years. With recent technological advances, the computational 
resources now available and interdisciplinary cooperation, further breakthroughs are 
inevitable. 
 
In TB, modelling has traditionally been empirical in nature, with clinical data providing the 
fuel for this top-down approach. Recently, projects have begun to use data derived from 
laboratory experiments and clinical trials to create mathematical models that describe the 
mechanisms responsible for the disease. 
 A systems medicine approach to infection modelling helps identify important biological 
questions that then direct future experiments, the results of which improve the model in an 
iterative cycle. This means that data from several model systems can be integrated and 
synthesised to explore complex biological systems. 
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1. Introduction 
Infectious diseases continue to be major worldwide health concerns: hepatitis C, malaria, the 
human immunodeficiency virus (HIV) and tuberculosis (TB) are ongoing pandemics. A third 
of the world population is currently infected with the TB bacillus; and even though 
therapeutic drugs have slowed the threat of HIV, there is no definitive cure or viable vaccine 
in sight. A new way of approaching the problem is needed; this can be achieved with a 
systems approach. By utilising expertise across disciplines, fresh perspective and new insights 
can be gained. 
 
Current modelling efforts span multiple levels in the disease system; population dynamics 
where the focus is on disease transmission, the progression from population level to 
individual level where heterogeneity is included, moving to the pathogen-host interactions 
ranging from molecular to cellular, to whole organism levels. Both biological experiments 
and mathematical modelling have been successful at elucidating the properties of a disease at 
a particular level, but a full understanding requires the integration of all scales. This remains a 
major challenge for systems medicine. Infectious diseases reflect an equilibrium between the 
host and the pathogen that is established and maintained by a broad network of interactions 
that occur on such scales. Maintenance and evolution of these interactions over a prolonged 
time frame adds further complexity to persistent infections. The understanding of a biological 
system requires the integration of data that are used to construct predictive models of the 
dynamic interactions between biological components of the complex pathogen-host system. 
 
Mathematical and computational techniques, together with available in vitro and in vivo 
experimental results can be used to generate realistic pathogen-host interaction models. Often 
these models involve iterative rounds of development, with testing and refinement using, for 
example, Bayesian methods. Models created in such a manner can be used to create testable 
hypotheses, with much learnt about the biological system in the process (see Figure 1). 
Ultimately, predictions can be made that can guide clinical practice. This iterative cycle is key 
to the systems approach and requires efficient integration of data with firm collaboration 
across disciplines. The technologies and computational resources now exist to realise this 
systems approach, we must take advantage of the potential these provide.  
 
In this chapter we review some basic epidemic modelling (section 2) before using two 
infectious disease case studies, HIV (section 3) and tuberculosis (section 4), to demonstrate 
how a systems approach, using simple mathematical techniques, can be used to further 
biological understanding and ultimately lead to changes in clinical practice. The focus in 
these sections is at the cellular level, describing viral/bacterial load dynamics. 
 
 
  
2. Epidemic modelling 
 
One motivating reason for modelling the spread of infectious diseases is to understand how 
future outbreaks can be prevented. This can be achieved in several different ways, such as 
isolation or imposed travel restrictions. These measures aim at reducing contact rates, i.e. to 
reduce the reproduction rate of the pathogen. The effect of these depends on the particular 
disease and the community under consideration. Vaccination is an alternative preventive 
measure, which reduces the pool of susceptible individuals by imparting immunity. 
 
In classical mathematical epidemic models [1], the total population number is assumed to be 
constant.  A small group of infected people is introduced into a large population and a model 
is used to describe the spread of infection within that population as a function of time.   
The model consists of three subpopulations of individuals:  
S(t) which denotes the number of people susceptible to the disease, 
I(t) which denotes the number of people who are infected and can transmit the disease and 
R(t) which denotes the number of removed people, i.e. those who were infected but are now 
recovered, are immune or have been isolated until they are recovered. 
 
Such models are known as SIR models, where transfer between populations is restricted to 
𝑆 ⟶ 𝐼 and 𝐼 ⟶ 𝑅. 
Some diseases include a class in which the disease is latent, E.  Such models are known as 
SEIR models. 
 
Assumptions of the SIR model: 
 The gain in the infective class is at a rate that is proportional to the number of 
infectious and susceptible people, rSI where r > 0 is a constant parameter.   
 The susceptible population is lost at the same rate.  The transfer of infected 
individuals to the removed class is proportional to the number of people who are 
infected, aI where a > 0 is a constant.  1/a is a measure of the time spent in the 
infectious state. 
 The incubation period is short enough to be negligible hence a susceptible person 
who catches the disease is infected immediately. 
 Every person has equal probability of coming into contact with one another. 
 
The model mechanism [2] is therefore,  
𝑑𝑠
𝑑𝑡
=  −𝑟𝑆𝐼, 
𝑑𝐼
𝑑𝑡
= 𝑟𝑆𝐼 − 𝑎𝐼, 
𝑑𝑅
𝑑𝑡
= 𝑎𝐼, 
where r > 0 is the infection rate and a > 0 is the removal rate of infectious individuals. 
Initial conditions are defined as S(0) = S0 > 0, I(0) = I0 > 0 and R(0) = 0 and the constant total 
population is built into the system via  
𝑑𝑆
𝑑𝑡
+
𝑑𝐼
𝑑𝑡
+
𝑑𝑅
𝑑𝑡
= 0 which implies that 
 𝑆 + 𝐼 + 𝑅 = 𝑁, where N is the total population. 
 
With this model, questions can be answered such as whether an infection will spread or not.  
If it does, how does it develop with time and critically, when will it start to decline?  Given r, 
a, S0 and I0 these questions can be addressed. 
 
This type of stochastic modelling looks at the properties of an epidemic by studying a given 
model and its parameters. It can be shown that the most important parameter in these SIR 
models is the basic reproduction rate of the disease, 𝑅0 =
𝑟𝑆0
𝑎
, where it can be shown that 
when R0 > 1, an epidemic ensues. Another important quantity when trying to avoid an 
outbreak is the critical vaccination coverage, which is defined as  
𝑣𝐶 = 1 −
1
𝑅0
 if R0 > 1, otherwise 𝑣𝐶 =  0.  
 
Even when trying to include as many realistic features in a model as possible there is a limit 
to how close a model can get to reality, and models can never completely predict what will 
happen in a given situation. It is, for example, nearly impossible to predict how people will 
adapt and change behaviour as a disease starts spreading. Having said this, models can still be 
very useful as guidance for health professionals when deciding about preventive measures 
aiming at reducing the spread of a disease. Much has been written describing mathematical 
models for infectious disease spread [3], [4], including stochastic epidemic models [5], [6], 
[7]. 
From traditional mathematical modelling it is clear that understanding and incorporating 
information from multiple scales can dramatically increase the power of such approaches. 
Thus, for example, emerging genome-wide genotyping and sequencing technologies are used 
to identify the biological mechanisms underlying the development of complex diseases and 
traits among populations. This allows models to build in host and pathogen features, but also 
points to the inclusion of larger, societal or population data. Such approaches have started to 
be deployed, for example in the recent epidemic outbreaks of Ebola in West Africa.  
Collectively, these approaches can help inform strategies for disease prevention and 
treatment. 
 
  
3. HIV modelling 
 
In 2013, ~1.5  million people died from HIV-related causes globally, having claimed an 
overall 39 million lives so far (World Health Organization, 2014). There is no cure for HIV 
infection but antiretroviral treatment (ART) can be used to control the disease. There is much 
still to be learnt about the virus and how best to administer effective treatment. Mathematical 
models developed over the last 20 years have helped to further understanding and provide 
new insights into the disease. 
 
One of the simplest mathematical models to describe HIV was proposed in 1995, where a 
simple linear first-order equation is used to describe viral load over time [8], 
𝑑𝑉
𝑑𝑡
= 𝑃 − 𝑐𝑉, 
where 𝑃 represents the viral production rate and 𝑐 is the viral clearance rate. Immune cells, 
fluid flow and absorption into other cells are combined to give the overall clearance of viral 
peptides, 𝑐.  
After introduction of the protease inhibitor it is assumed that the drug is completely effective, 
so the drug will block all viral production after being introduced. Under this assumption, 
𝑃 =  0 which leaves the simple equation 
𝑑𝑉
𝑑𝑡
= −𝑐𝑉 ⇒ 𝑉(𝑡) = 𝑉0𝑒
−𝑐𝑡 , 
where 𝑉0 is the mean viral concentration in the plasma before treatment. 
Using linear regression to examine the relationship between ln 𝑉 against 𝑡 gives an estimate 
for 𝑐 and hence for the half-life of the virus in the plasma, 𝑡1
2
= ln
2
𝑐
.  
 
If an assumption is then made that the levels of viral load measured in the plasma remain 
fairly constant before treatment begins, i.e. the patient is in a quasi-steady state, 
𝑑𝑉
𝑑𝑡
 =  0, then 
by knowing 𝑐 and the initial virus concentration 𝑉0, the viral production rate before therapy 
can be computed, i.e., 𝑃  =  𝑐𝑉0. It should be noted, however, that as this calculation is based 
on the assumption that the drug completely blocks virus production. This assumption is 
unlikely to hold, and so, experiments would measure the rate of virus clearance in the face of 
some residual production, and the gradient of viral decline would therefore be a lower bound 
of the true clearance rate. Further models with added complexities have been developed from 
this simple framework (see [9] for a comprehensive review). 
 
By using relatively simple modelling techniques and trivial mathematics, fundamental 
information has been gained about the underlying biological mechanisms of the disease. 
These developments have made a substantial impact on our thinking and understanding of 
HIV infection. For example, because the disease can take around 10 years to develop, many 
thought that the disease process would be slow and treatment could be delayed until 
symptoms appeared. Patients were therefore not monitored very aggressively. Modelling, 
coupled with appropriate experiments, has revealed that HIV is a dynamic disease 
encompassing various different time scales. An extremely simple model involving a single 
linear ordinary differential equation (described above), when applied to the interpretation of 
clinical data, gave the first quantitative estimate of how rapidly HIV was being produced and 
cleared [8], [10]. 
 
Rigorous analysis of previously conducted in vivo experiments also prompted the practice of 
using prolonged therapy with effective drug combinations. Calculations revealed that in an 
average HIV-infected person, around 1010 viral particles are produced and released into 
bodily fluids per day [11]. It was therefore calculated that an infected person could go through 
about 200 replication cycles per year, with the possibility of mutating at each replication With 
this new information, the rapid evolution of HIV could easily be understood. Therapy with a 
single drug, in which a few mutations were all that were required for resistance to arise, was 
concluded to be a poor strategy. This demonstrated the need for combination therapy.  
 
Adding complexity into the modelling by considering multiple cell populations, it was found 
that the virus concentration in plasma has a two-phase decline. By using data obtained from 
patients responding well to combination therapy, estimates of how long therapy would need 
to be given to clear the cells responsible for producing the observed levels of virus were 
calculated. This led to the practice of antiretroviral drugs being taken for at least 2 or 3 years 
after the virus is no longer detectable in the blood [9]. This modelling work also began the 
process of quantifying both the level and the role of latently and long-lived infected cell 
populations in HIV infection. 
 
These important breakthroughs in the understanding of the HIV and its treatment have arisen 
from relatively trivial mathematical modelling exercises. This effectively demonstrates how 
systems based, interdisciplinary approaches can make huge advances in medical treatment. 
 
  
4. Tuberculosis modelling 
 
Tuberculosis remains one of the leading causes of death by infectious disease, second only to 
HIV/AIDS. It is estimated that one third of the world population is latently infected by 
Mycobacterium tuberculosis, with 2012 seeing 8.6 million people falling ill and 1.3 million 
dying from the disease (World Health Organization, 2014). 
Although well-administered short-course chemotherapy is clinically effective [12], there are 
several concerns surrounding current TB treatment. The emergence of multi-drug and 
extensive drug resistance is a major burden since it could lead to an increase of tuberculosis 
cases that are hard or impossible to treat [13]. Another major issue in tuberculosis treatment is 
its duration, which is currently a minimum of 6 months. Shortening the duration of effective 
TB therapy would mean better patient compliance and lower rates of relapse and drug 
resistance.  
Traditional approaches in tuberculosis research are based on pre-clinical experiments, in vitro 
and in vivo. These systems each have limitations and often, desired experiments are not 
feasible due to laboratory or ethical issues. Mathematical modelling alongside these assays 
allows hypotheses to be developed and tested, and hence further understanding of the disease 
by suggesting innovative approaches.  
In the last 20 years, mathematical models have provided major insights in the knowledge of 
tuberculosis pathogenesis [14], [15], [16]. During this time, progress has also been made in 
the quantitative description of both pharmacokinetics (PK) and in vitro pharmacodynamics 
(PD) of antituberculosis drugs [17], [18], [19]. Mathematical models that arise from a systems 
approach offer a unique potential to establish quantitative links across multiple biological 
scales. Different mathematical systems capture biological complexity best at individual 
scales. Once mathematical models adequately describe these biological complexities on an 
individual scale, integrating the scales will then be vital in order to understand the overall 
dynamics of this infectious disease. In this chapter we focus on modelling at the cellular level, 
modelling bacterial load detected in clinical sputum samples.  
It has long been noted in tuberculosis patients that decline in bacterial numbers appears to 
have two phases of decline. Many studies have employed non-linear mixed effects modelling 
techniques to fit bi-exponential functions to clinical trial data [20], [21]. For example, in [21], 
a bi-exponential model of the form 
log10 𝐶𝐹𝑈 = log10(𝑒
𝜃1𝑒−𝑑𝑎𝑦𝑒
𝜃2 + 𝑒𝜃3𝑒−𝑑𝑎𝑦𝑒
𝜃4  ) 
was used, where a log10 transformation of the response and a variance function were used to 
account for heteroscedasticity and an exponentiated parameterisation was used to enforce 
positivity of the parameters. These authors showed that the bi-exponential models provide a 
significantly better fit than a mono-exponential model. As it is known from in vitro studies 
that Mycobacterium tuberculosis bacteria exist in more than one cell state, the interpretation 
of the two-phase decline is that two subpopulations of Mycobacterium tuberculosis are 
present in the sputum, each declining at different rates. This has led to hypotheses about 
“dormant” cells being responsible for latent disease, and relapse. Consequently huge effort 
has gone into researching this less metabolically active subpopulation of cells. 
Traditional statistical modelling techniques have also been useful for identifying trends in 
clinical data sets. As tuberculosis is a slow growing organism (with a generation time 
between 17.5-56 hours [22], [23]), it can take time to obtain microbiological results to assess 
the progress of treatment. For this reason, modelling techniques have been used to identify 
biomarkers of success. Thus the 8-week biomarker of culture conversion was created as the 
most used indicator of treatment outcome [24]. More recent modelling efforts have been 
employed to investigate the reliability of using baseline bacterial load as an indicator for later 
relapse [25]. 
Although statistical modelling techniques are very powerful, fitting to the clinical data 
empirically in order to provide future predictions, the differential equations describing the 
system are employed without reference to the mechanisms underlying the biological system 
and so little can be learnt about the basic biology using these methods.  
In contrast to statistical modelling, mathematical or mechanistic models can summarise 
current knowledge, and in their development, a greater understanding of the biological system 
can be gained. They can be used to highlight gaps in current knowledge and identify tractable 
biological questions. The mechanistic approach also allows us to predict how a system will 
shift when underlying processes change. If mechanistic models are correctly specified, they 
should provide better simulation and prediction properties than many current empirical 
models.  
 
In TB, mechanistic models use available clinical and preclinical data to pre-define parameter 
values before solving the set of differential equations describing the biological system. 
Although there is often uncertainty when assigning parameter values, common parameter 
estimation techniques such as profile likelihood can be used to analyse parameter sensitivity 
in the system. A huge advantage of mechanistic modelling is that we are able to analyse the 
effect that parameters have on the bacterial load. For example, by altering killing parameters, 
the effect of new regimens on time to culture conversion can be analysed. Drugs targeting 
bacteria in different cell states can also be investigated. These simulations provide a surrogate 
for experiments that would not be feasible in vivo or in vitro.  
 
This systems medicine approach means that during development of mechanistic models, 
important biological questions can be identified and therefore direct future experiments, the 
results of which will feed back into the model (see Figure 1). Hence data from several model 
systems (animal, human, bacterial, and computational) can be integrated and synthesised to 
explore the complex biological system and address relevant questions. 
 5. TB-HIV co-infection 
 
For tuberculosis patients co-infected with the HIV, the disease becomes more complex to 
treat. Most TB-HIV models address the epidemiology of co-infection. In 1992, the first model 
was published to quantify the consequences of the emerging TB-HIV epidemic [26]. In 2003, 
it was found that Antiretroviral therapy (ART) must be started early if expansion to the access 
of the therapy was to result in the increased control of TB [27]. Isoniazid preventative therapy 
(IPT) has also been modelled [28], [29], resulting in predictions of 34% - 100% of reduction 
of risk of TB. Models have also been used to explore enhancements to DOTS-based 
programmes [30], and also to inform policy on implementation of new interventions and tools 
[31]. In a recent article, [32] suggest a modelling TB-HIV research agenda, based on expert 
discussions at a meeting convened by the TB Modelling and Analysis Consortium. Here they 
identified high-priority areas for future modelling efforts; the difficult diagnosis and high 
mortality of TB-HIV, the high risk of disease progression, TB health systems in high HIV 
prevalence settings, uncertainty in the natural progression of TB-HIV and combined 
interventions for TB-HIV. The realisation of these aims relies on a systems based approach, 
where modellers’ and key stakeholders’ collaborative efforts result in tangible progress. 
Models that address the pathology of TB-HIV infected patients are also presented in the 
literature. Some studies attempt to understand how Mycobacterium tuberculosis affects the 
dynamic interaction of HIV-1 and the immune system [33] ,[34]. More modelling in this area 
is needed if we are to understand the complex interactions between these two pathogens, and 
hence start to provide recommendations for improvement in treatment plans. 
 
    
  
6. Conclusions 
 
Infectious diseases such as HIV and tuberculosis are major global health concerns and much 
is still unknown about the diseases. In order to aid improvements in treatment, mathematical 
and computational models are needed to provide a new insight.  
 
Interdisciplinary research is often criticised as researchers from other specialties are ignorant 
of many fundamental concepts in the discipline they are new to. However, this can also bring 
advantages. In model development, there is a danger that existing beliefs can inappropriately 
influence judgements about model assumptions and results. When mathematicians and 
computer scientists are used to develop models, however, they are not influenced by current 
dogmas in the field and can provide a fresh perspective on the problem. 
 
Mathematics provides a precise quantitative language to describe the relation between 
variables and changes in states, and in medicine we can represent mathematically the clinical 
course of disease, the distribution of disease across populations and over time, and the 
mechanisms that generate disease. We have seen in this chapter that relatively simple 
mathematics has led to huge leaps forward in the understanding of both HIV and tuberculosis 
infection. With more sophisticated analysis and ever increasing computational power, the 
possibility of significant breakthroughs using this systems-based approach to medical 
research presents an exciting prospect. 
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Figures 
Figure 1: This schematic describes dynamic model development. Prior knowledge and data 
from laboratory results help to develop an initial model. Once constructed, this model is 
refined. After this, an iterative cycle begins where the model is tested against the available 
data until the model is deemed to adequately describe this data. Once this cycle is complete, 
the last iterative cycle is embarked upon where predictions are made and ultimately validated 
against an independent data set. 
 
